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ABSTRACT
Objective: To investigate the role of known multiple sclerosis (MS)-associated genetic variants in
MS familial aggregation, clinical expression, and accuracy of disease prediction in sporadic and
familial cases.
Methods: A total of 1,443 consecutive patients were screened for MS and familial autoimmune
history in a hospital-based Italian cohort. Among them, 461 sporadic and 93 familial probands
were genotyped for 107 MS-associated polymorphisms. Their effect sizes were combined to
calculate the weighted genetic risk score (wGRS).
Results: Family history of MS was reported by 17.2% of probands, and 33.8% reported a familial
autoimmune disorder, with autoimmune thyroiditis and psoriasis being the most frequent. No
difference in wGRS was observed between sporadic and familial MS cases. In contrast, a lower
wGRS was observed in probands with greater familial aggregation (.1 first-degree relative
or .2 relatives with MS) (p 5 0.03). Also, female probands of familial cases with greater familial
aggregation had a lower wGRS than sporadic cases (p 5 0.0009) and male probands of familial
cases (p 5 0.04). An inverse correlation between wGRS and age at onset was observed (p 5
0.05). The predictive performance of the genetic model including all known MS variants was
modest but greater in sporadic vs familial cases (area under the curve 5 0.63 and 0.57).
Conclusions: Additional variants outside the known MS-associated loci, rare variants, and/or
environmental factors may explain disease occurrence within families; in females, hormonal
and epigenetic factors probably have a predominant role in explaining familial aggregation. The
inclusion of these additional factors in future versions of aggregated genetic measures could
improve their predictive ability. Neurol Neuroimmunol Neuroinflamm 2015;2:e129; doi: 10.1212/
NXI.0000000000000129
GLOSSARY
AAO 5 age at onset; AID 5 autoimmune disease; AT 5 autoimmune thyroiditis; AUC 5 area under the curve; CD 5 celiac
disease; CI 5 confidence interval; EDSS 5 Expanded Disability Status Scale; fMS 5 familial MS; GWAS 5 genome-wide
association studies; HC 5 healthy controls; HLA 5 human leukocyte antigen; IBD 5 inflammatory bowel disease; IDDM 5
insulin-dependent diabetes mellitus;MHC5major histocompatibility complex;MS5multiple sclerosis;MSSS5MSSeverity
Score; OCB 5 oligoclonal bands; OSR 5 San Raffaele Hospital; RA 5 rheumatoid arthritis; ROC 5 receiver operating char-
acteristic; SLE 5 systemic lupus erythematosus; sMS 5 sporadic MS; SNP 5 single nucleotide polymorphism; wGRS 5
weighted genetic risk score.
Multiple sclerosis (MS) is an inflammatory disease of the CNS caused by the interaction
between genetic and nongenetic risk factors.1
Nowadays, the association between the major histocompatibility complex (MHC) region and
MS is well-established.2,3 Very recently, knowledge about MS-associated genetic variants has
increased thanks to genome-wide association studies (GWAS) that validated the effect of 103
non-MHC loci in the genetic architecture of the disease.4,5 The majority of non-MHC risk loci
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have known immunologic functions, and
some of them are also shared across different
autoimmune diseases (AIDs). Moreover, MS
can coexist with other AIDs within individuals
and their families,6 suggesting a shared genetic
architecture between MS and other AIDs.7
Taken one by one, MS-associated loci make
a very small contribution to disease risk. The
combined aggregation of genetic variants is a
simple measure to explore the influence of
the cumulative genetic burden on disease sus-
ceptibility and clinical expression.
In the present study, we investigated the role
of the established MS loci in explaining the
familial aggregation for MS in a single-center,
hospital-based Italian cohort. For this purpose,
a cohort of ;1,500 patients was screened for
familial aggregation of MS and AIDs, and in a
subset the weighted genetic risk score (wGRS)
was calculated to take into account the com-
bined influence of the susceptibility loci on MS
familial aggregation. As secondary and tertiary
outcomes, we investigated the impact of these
genetic variants in explaining the clinical dis-
ease characteristics and their predictive capabil-
ity on disease status.
METHODS Patient screening. Between July and December
2011, consecutive Italian patients with MS (diagnosed according
to McDonald criteria and further revisions8,9) who had had at
least one appointment at San Raffaele Hospital (OSR) MS center
were screened for familial history of MS and/or AIDs. A struc-
tured questionnaire was administered during an outpatient visit
to all patients willing to participate in the study. Specifically, we
assessed for familial history ofMS, clinically isolated syndrome, and the
following AIDs: insulin-dependent diabetes mellitus (IDDM),
inflammatory bowel diseases (IBDs), autoimmune thyroiditis (AT),
rheumatoid arthritis (RA), systemic lupus erythematosus (SLE),
psoriasis, celiac disease (CD), and neuromyelitis optica spectrum
disorder. An open question regarding the occurrence of other AIDs
was also included.
Probands with at least one relative affected by MS were
defined as patients with familial MS (fMS), whereas probands
without any familial history of the disease were defined as patients
with sporadic MS (sMS). For each patient with fMS, we defined
the number and the degree of kinship of affected relatives. For
each proband, we screened for the number of relatives affected
by AIDs and their degree of kinship. We also calculated the recur-
rence risk ratio of siblings for MS, the lambda siblings (ls), which
is the ratio between the risk of disease in siblings of an affected
individual and the disease population prevalence, estimated at
100/100,000 in Italy.10
In addition, the following clinical and paraclinical informa-
tion was collected when available: age at visit, age at disease onset
(AAO), sex, disease duration, clinical course, Expanded Disability
Status Scale (EDSS) score, MS Severity Score (MSSS), and oligo-
clonal band (OCB) status.
Genotyping data and wGRS calculation. Among the
screened patients, genotyping data were already available for
554 patients. Of these, 104 patients were genotyped at the Well-
come Trust Sanger Institute using the Illumina Human660-
Quad chip.5 248 additional cases were genotyped using the
Illumina OmniExpress array at OSR11; the remaining 202
patients were genotyped using Illumina HumanOmni2.5 arrays.
A cohort of 258 Italian healthy controls (HC) recruited at
OSRMS center were also included in the analyses. These individ-
uals did not have any degree of kinship with the patients with MS
enrolled in the study and they did not have a known familial
history for MS. They were genotyped using the Illumina
OmniExpress array at OSR.12
The wGRS was calculated as previously described,11 combining
the odds ratio of 106 non–human leukocyte antigen (HLA) MS
variants (table e-1 at Neurology.org/nn)4,5 and one tagging single
nucleotide polymorphism (SNP) for the HLA-DRB1*1501 allele.
Quality controls were performed as described elsewhere.5,12 When-
ever a specific SNPwas absent in one of the arrays, the best available
proxy according to HapMap release 24 was considered for the
analyses; in this case, the r2 value between the original and proxy
SNP was included in the wGRS calculation. The score was also
calculated after the exclusion of the HLA polymorphism in order to
evaluate the contribution of non-HLA risk variants (wGRS–non-
HLA). For the HLA-DRB1*1501 allele, since the tagging SNP
rs313538813 was not available on used arrays, the best available
proxy (rs9271366) was chosen (r2 5 0.974, D’ 5 1.0 according
to HapMap release 24). Patients with genotypes with more than
10%missing were excluded; patients with genotypes with less than
10% missing were included in the analysis, setting the missing
SNPs as heterozygous.
Receiver operating characteristic (ROC) curves were com-
puted to assess the wGRS performance in discriminating between
cases and controls, and the area under the curve (AUC) was cal-
culated. Differences in the predictive performance of the genetic
models were tested using the DeLong test for correlated ROC
curves in the R package “pROC.” Statistical analyses were per-
formed using the nonparametric Mann-Whitney test and the
Pearson correlation implemented in GraphPad software v.5.
Standard protocol approvals, registrations, and patient
consents. The study was approved by the institutional ethics
committee (“NEUFAM-01” and “NEUFAM02” protocol). Each
enrolled patient agreed to participate in the study by signing the
informed consent. Blood sample collection was performed after
the consent form was signed.
RESULTS Familial aggregation for MS and AIDs. A
total of 1,443 Italian patients with MS were screened
using a structured questionnaire in order to assess the
occurrence of MS and/or any other AID within the
family. The participation rate was 96.2%. A total of
248 probands (17.2%) reported another family mem-
ber affected by MS (fMS). Among them, 202
(81.5%) had 1 affected relative, 39 (15.7%) had 2
affected relatives, 6 (2.4%) had 3 affected relatives,
and 1 (0.4%) had 5 affected relatives. Demographic
and clinical characteristics of the cohort are reported
in table 1. The subset of patients with available gen-
otyping data (n 5 554) was older and had longer
disease duration and less severe disease than the entire
screened cohort. However, the genotyped patients
were representative of the entire population followed
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at OSR (n 5 2,500) in terms of age, sex, disease
course, disease duration, EDSS score, and disease
severity. When considering genotyped patients with
MS, we observed no differences between fMS (n 5
93) and sMS (n 5 461) in terms of sex, age, AAO,
disease duration, disease severity, or OCB status.
These characteristics are reported in table 2 and are
in line with data from the literature.14
Based on the information available for each proband,
the crude recurrence risk ratio of siblings15 for MS was
calculated. Considering an MS prevalence of 1/1,000 in
Italy, the estimate of ls was 23.3, in line with what has
been reported previously in the literature.16
Regarding the aggregation for AIDs, 33.8% of pa-
tients (n 5 488) reported a family history of
autoimmunity. Specifically, 290 (59.5%) had 1 rela-
tive, 105 (21.5%) had 2 relatives, 25 (5.1%) had 3
relatives, 5 (1%) had 4 relatives, and 5 (1%) had 5 or
more relatives affected by AIDs. The remaining 58
probands (11.9%) did not report the exact number of
relatives affected by AIDs. The distribution of AIDs
in fMS and sMS is plotted in figure e-1. The most
common conditions were AT (reported in 142 rela-
tives) and psoriasis (reported in 137 relatives),
followed by 124 relatives with RA, 90 relatives with
IDDM, 52 relatives with CD, 33 relatives with SLE,
and 32 relatives with IBD. Forty-five relatives were
affected by other AIDs, including myasthenia, sclero-
derma, polymyositis, and vitiligo.
Impact of wGRS on familial aggregation. As expected,
the wGRS was significantly higher in patients with
sMS and fMS than HC: the mean wGRS (SE) was
10.35 (0.04) in HC compared to 10.78 (0.04) in
sMS (p , 0.0001) and 10.68 (0.09) in fMS (p 5
0.01) (figure 1A, table e-2). Considering the wGRS–
non-HLA, similar results were obtained: mean wGRS
was 10.18 (0.03) in HC vs 10.46 (0.02) in sMS (p ,
0.0001) and 10.37 (0.06) in fMS (p 5 0.01). How-
ever, no difference in wGRS was observed between
sMS and fMS, regardless of whether or not the HLA
variant was included in the genetic burden calculation
(p5 0.14 and 0.16, respectively) (figure 1A, table e-2).
When limiting the analyses to patients with fMS
with a higher degree of familial aggregation (probands
with one first-degree affected relative or with at least 2
affected relatives [first category in figure 1A]), a signif-
icantly lower wGRS was observed in fMS than sMS:
10.52 (0.13) vs 10.78 (0.04), p 5 0.03 (figure 1A).
Considering the wGRS–non-HLA, the same compar-
ison showed a trend toward statistical significance
(10.29 vs 10.46, p 5 0.06). In contrast, we did not
Table 1 Demographic and clinical features of the studied cohort
MS probands with genetic data (n 5 554) Entire MS cohort (n 5 1,443) p Value
Female:male ratio 2:1 (370:184) 2:1 (964:479) NS
Age, y 42.8 6 10.1 41.0 6 10.7 ,0.001
Disease course BOMS (n 5 537) BOMS (n 5 1,400) NS
PrMS (n 5 15) PrMS (n 5 23)
Disease duration, y 13.7 6 6.7 12.0 6 7.9 ,0.001
Age at disease onset, y 28.9 6 9.3 28.9 6 9.0 NS
EDSS score 1.5 1.5 NS
MSSS 2.08 6 1.9 2.72 6 2.1 ,0.001
OCB positive/negative 390/33 918/86 NS
Abbreviations: BOMS 5 bout-onset MS; EDSS 5 Expanded Disability Status Scale; MS 5 multiple sclerosis; MSSS 5 MS
Severity Score; NS 5 not significant; OCB 5 oligoclonal bands; PrMS 5 progressive-onset MS.
Demographic and clinical characteristics of the genotyped patients are compared with those of the entire cohort. For age,
disease duration, age at onset, and MSSS, the mean value6 SD is indicated. For EDSS score, the median value is reported.
Significant p values (p , 0.05) are reported in the last column.
Table 2 Demographic and clinical features of patients with fMS and sMS with
available genetic data
fMS (n 5 93) sMS (n 5 461) p Value
Female:male ratio 2.6:1 (67:26) 1.9:1 (303:158) NS
Age, y 42.8 6 10.7 42.9 6 10.0 NS
Disease course BOMS (n 5 91) BOMS (n 5 446) NS
PrMS (n 5 2) PrMS (n 5 13)
Disease duration, y 13.8 6 6.4 13.8 6 6.7 NS
Age at disease onset, y 28.9 6 10.1 29.0 6 9.1 NS
EDSS score 1.5 1.5 NS
MSSS 2.08 6 1.5 2.08 6 1.9 NS
OCB positive/negative 68/4 322/29 NS
Abbreviations: BOMS 5 bout-onset multiple sclerosis; EDSS 5 Expanded Disability Status
Scale; fMS 5 familial multiple sclerosis; MSSS 5 Multiple Sclerosis Severity Score; NS 5
not significant; OCB 5 oligoclonal bands; PrMS 5 progressive-onset multiple sclerosis;
sMS 5 sporadic multiple sclerosis.
Demographic and clinical characteristics of genotyped patients with fMS are compared
with patients with sMS. For age, disease duration, age at onset, and MSSS the mean
value 6 SD is indicated. For EDSS score, the median value is reported.
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observe any difference between probands with one
affected relative with second or more degree of kinship
(second category in figure 1A) and patients with sMS
(p 5 0.94 for wGRS and p 5 0.78 for wGRS–non-
HLA).
We also assessed the impact of the known MS loci
on the combined aggregation for MS or other AIDs;
however, we did not observe any difference between
patients without familial history of MS or AIDs and
patients with familial history of MS or AIDs (p 5
0.38, data not shown).
We then performed analyses stratified by sex and
observed that female patients with fMS had a lower
wGRS than female patients with sMS: 10.62 (0.10)
vs 10.78 (0.04), p 5 0.04 (figure 1B, table e-3). This
difference became even more significant when compar-
ing female patients with fMS with a higher degree of
familiarity (first category females) with female patients
with sMS: 10.35 (0.15) vs 10.78 (0.04), p 5 0.0009
(figure 1B, table e-3). Moreover, a lower wGRS was
found in first category females compared with female
patients with a lower degree of familiarity (second cat-
egory females) (10.35 vs 10.79, p 5 0.02) and first
category males (p 5 0.04) (figure 1B, table e-3). Sim-
ilar results were obtained in the wGRS–non-HLA
analysis (data not shown). No differences were found
in male patients, even if sample size was lower (data not
shown).
wGRS and MS clinical features. In the second part of
our study, we assessed the association between wGRS
and MS clinical characteristics. We observed an
inverse relationship between genetic burden and
AAO: patients with higher wGRS had an earlier
AAO (p 5 0.05). This relationship was stronger
when excluding the HLA-DRB1*1501 variant in
the score calculation (p 5 0.01) (figure 2A). After
stratification for MS familiarity, the relationship
between genetic burden and AAO was confirmed in
sMS (figure 2B) but not in fMS (figure 2C), probably
because of the limited sample size. We also observed
that wGRS did not correlate with disease severity
measured by MSSS or with the presence of OCB.
wGRS and prediction of disease status. Finally, we as-
sessed the predictive performance of different genetic
models using ROC curves. The wGRS score calcu-
lated based on only the HLA-DRB1*1501 variant
allele had a very limited capacity to discriminate
between patients with MS and HC (AUC 5 0.55,
95% confidence interval [CI] 0.52–0.58, figure 3A).
The AUC increased to 0.59 (95% CI 0.55–0.63) and
to 0.61 (95% CI 0.57–0.65) when including wGRS–
non-HLA and HLA alleles for building the model,
respectively (figure 3A). The difference in predictive
performance was significant between the model con-
sidering only HLA-DRB1 and the one considering
HLA-DRB1*1501 plus 106 SNPs (p 5 0.0008).
We then evaluated the predictive capability of the
different genetic models separately in sMS (figure
3B) and fMS (figure 3C). We observed that the full
model (HLA-DRB1*1501 plus 106 genetic loci) was
better at discriminating patients with sMS from HC
(AUC 5 0.63, 95% CI 0.58–0.67, figure 3B)
than discriminating patients with fMS from HC
Figure 1 Distribution of the wGRS in HC and patients with sMS and fMS
(A) The box plot describes the weighted genetic risk score (wGRS) distribution in healthy con-
trols (HC) and patients with sporadic multiple sclerosis (sMS) and familial multiple sclerosis
(fMS). (B) The same analysis stratified by sex. Sample size is indicated at the bottom of each
box plot. The horizontal line in the box represents themedian of the sample set, the hinges rep-
resent the 25th and 75th percentiles, and the whiskers represent the 5th and 95th percen-
tiles. The p values between the different groups are reported at the top of the box plots. 1st
category: probands with one first-degree affected relative or with at least 2 affected relatives;
2nd category: probands with one affected relative with second or more degree of kinship.
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(AUC 5 0.57, 95% CI 0.50–0.64, figure 3C);
however, the difference in the predictive capability was
not statistically significant (p5 0.13). Moreover, in the
sMS subgroup, the full model had a statistically better
predictive performance than the model considering only
HLA-DRB1 (p 5 0.00006). Finally, no difference in
predictive capability was found in female probands
compared with male probands (AUC 5 0.62, 95%
CI 0.55–0.68 vs AUC 5 0.60, 95% CI 0.54-0.66;
p 5 0.65).
DISCUSSION In recent years, significant efforts have
been made to understand the genetic architecture of
MS, allowing a deeper knowledge of the pathogenetic
mechanisms triggering the disease. More than 100 loci
are now confirmed to be associated with MS, and this
number is expected to increase in the near future
thanks to additional GWAS combined with next-
generation sequencing efforts. The challenge that the
MS community has to face now is how to integrate
this information into clinical practice. We performed
this study in order to assess the role of known
genetic variants in explaining familial aggregation,
clinical phenotypes, and prediction of disease status
by using an aggregate measure to estimate genetic
burden at the individual level.
We studied a single-center, hospital-based cohort of
Italian patients with MS who were screened for familial
risks of MS and AIDs. All consecutive patients with
MS who had had at least one appointment at OSR
during a 6-month period were asked to complete a
questionnaire, and the participation rate was very high
(96.2%). Family history of MS was reported by 17.2%
of probands, which is in line with data reported in the
literature,15–17 particularly a Canadian study15 in which
19.9% of patients reported at least one relative with
MS and a Belgian cohort17 in which 15.4% of patients
had at least one affected relative in the pedigree. These
data suggest that our cohort is representative of the
general MS population in the Northern hemisphere.
Then we evaluated how AIDs cluster in families of
MS probands. Autoimmune conditions were common
in these families, with AT being the most frequent con-
dition, followed by psoriasis and RA. This suggests the
presence of common underlying pathophysiologic
mechanisms, which could be explained by shared
genetic and/or environmental risk factors. Specifically,
there are already several cases of genetic variants,
involving both HLA and non-HLA loci, known to
be implicated in the susceptibility to different AIDs.18
The subset of patients with available genotype
information for the known MS loci was then studied
to evaluate how susceptibility variants may have an
impact on disease epidemiology and clinical manifes-
tations. In our cohort, both wGRS and wGRS–non-
HLA were statistically higher in patients with MS
than HC, in agreement with previous reports from
American and Norwegian data sets in which the
wGRS was calculated using almost half of the cur-
rently available MS susceptibility variants.14,19 More
recently, the analyses performed on a UK cohort con-
sidering all known genetic variants revealed similar
Figure 2 Correlation between wGRS and age at onset
The figure shows the correlation between weighted genetic risk score (wGRS) and age at
onset in all probands (A), patients with sporadic multiple sclerosis (MS) (B), and patients with
familial MS (C). The linear regression lines are drawn in solid red and green for wGRS and
wGRS without the inclusion of human leukocyte antigen (HLA) in the calculation, respec-
tively. The p values from the Pearson nonparametric correlation test and the r estimates
are shown near the regression lines. n.s. 5 not significant.
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results.20 Previous studies on the American MS cohort
suggested higher aggregation of susceptibility variants
in multicase compared with single-case MS fami-
lies.14,21 However, this observation was not replicated
in a Norwegian data set.19 Harbo et al.19 did not find
differences in genetic burden between fMS and sMS.
We cannot exclude the possibility that differences in
genetic burden between fMS and sMS might emerge
by increasing sample size. However, population-based
differences could explain the different findings
observed in our study and the study by Harbo et al.
compared to those from the American cohort.14
In addition, in the present cohort, a lower wGRS
was observed when considering a subset of MS pro-
bands with a high degree of familiarity (first category
in figure 1A). We argue that common genetic variants
associated with MS explain little of the familial aggre-
gation of MS in European populations.
We can speculate that other factors, such as rare/
private variants, environmental factors, or epigenetic
mechanisms, are shared within families, especially in
those with a high degree of familiarity. It is interesting
that the analysis stratified by sex revealed that female
probands had a lower wGRS than male probands (fig-
ure 1B). This observation could be explained by the
different sample size, but it also points to possible hor-
monal factors involved in explaining susceptibility and
incidence of the disease in females compared to males,
together with putative epigenetic mechanisms with
prevalent maternal transmission.22 These preliminary
results need to be interpreted with caution due to the
small size of the groups after stratification, and they
should be confirmed in additional samples to establish
this association with confidence.
In agreement with previous reports,19 we con-
firmed that individuals with a higher wGRS have a
lower AAO, suggesting that carrying an increased
number of susceptibility variants might influence
the clinical expression of MS by shortening the dura-
tion of the silent clinical phase.
Finally, we observed that when the wGRS was
used as a predictor of disease status, the predictive
performance improved when adding all known MS
susceptibility variants to the model; nonetheless, the
Figure 3 Predictive performance of wGRS
The receiver operating characteristic curves are plotted
considering 3 different models: weighted genetic risk score
(wGRS) calculated with only with HLA-DRB1 alleles (green
line), wGRS non-HLA (blue line), and wGRS calculated includ-
ing all the 106 known genetic variants plus HLA allele (red
line). The area under the curve (AUC) was calculated for
the 3 different models, assessing the predictive capability
in the entire multiple sclerosis (MS) cohort (A), in the sub-
group of patients with sporadic MS (B), and in the subgroup
of patients with familial MS (C). HLA 5 human leukocyte
antigen; SNP 5 single nucleotide polymorphism.
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wGRS measure still has limited predictive value for
discrimination between cases and controls (figure
3A). The same analyses stratified by sMS and fMS
suggested that known MS genetic variants are better
at distinguishing patients with sMS from HC than
patients with fMS (figure 3, B and C). These results
are consistent with what was observed in our primary
analysis.
The present study has several limitations: (1) the
epidemiologic data were gathered indirectly through
interviews with patients and not from the relatives
themselves using a family history method; (2) the lim-
ited sample size of our cohort could have had an
impact on our observations, and additional analyses
in bigger cohorts are required to confirm our findings;
(3) the lack of an independent replication cohort does
not provide a robust framework to assess the impor-
tance of our findings for the Italian MS population
as a whole; and (4) given that our genotyped popula-
tion is a subset with longer duration and less severe dis-
ease, our findings could require extension to a more
representative genotyped sample or the entire popula-
tion screened to assess whether wGRS has a more
important role when incorporating a higher proportion
of patients with more severe disease.
Taken together, our results suggest that genetic
data are still unlikely to be useful on their own for as-
sessing disease prediction and familial aggregation in
clinical settings, even if they may contribute to the
exploration of how genetic risk contributes to clinical
phenotypes like AAO. It is more likely that a predic-
tive algorithm using MS susceptibility loci might pro-
vide useful information when incorporating both
common and rare variants as well as other dimensions
of information such as environmental risk factors or,
ultimately, blood biomarkers or imaging data. More-
over, it is clear that genetic factors are not the only
players in explaining familial aggregation and that
the epistatic interactions between genetic and nonge-
netic factors should be considered in building an up-
dated algorithm able to take into account the complex
and polygenic nature of MS, especially in families
with female predominance.
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